UK-based Monument Therapeutics has partnered with the US Foundation for the National Institutes of Health (FNIH) to study ...

Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for ...

Cambridge Cognition said its digital cognitive assessment technologies supported the early development of MT1988 and were "instrumental" in establishing Monument's foundational biomarker strategy.

CAMBRIDGE, UK - Monument Therapeutics has partnered with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment for cognitive impairment associated with ...

CAMBRIDGE, UK - Monument Therapeutics has partnered with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment for cognitive impairment associated with ...

“Securing robust patent protection for our proprietary biomarkers is a top priority, and we are pleased to announce the grant of this U.S. patent supporting our MT1988 program for cognitive ...

Monument's treatment MT1988 is complementary to existing drugs for schizophrenia, including the newly-approved drug Cobenfy, which was originally developed by Karuna Therapeutics and acquired by ...

Spearheading the MT1988 clinical trial are Yale School of Medicine’s Dr Scott Woods and Dr Youngsun Cho, as well as Brigham and Women’s Hospital’s Dr Martha Shenton and Dr Ofer Pasternak.

The AIM-traded firm said the clinical study would evaluate MT1988, a novel therapy targeting cognitive impairment associated with schizophrenia, in a proof-of-principle trial under the ...

(Alliance News) - Cambridge Cognition Holdings PLC on Tuesday said Monument Therapeutics, in which it holds a 20% stake, has partnered up on the development of a novel treatment for cognitive ...